After more than a year of planning, Novartis shareholders have given the green light for the company to spin off its Sandoz unit, paving the way for Sandoz to become a standalone generics and biosimilars business “on or around” 4 October.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?